TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04432116

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: virtual reality 1
Description: the subject is in a virtual waiting room, there is no other intervention. The principle of this intervention is to make the subject wait with as little interfering events as possible

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: virtual reality 2
Description: Subjects are in a virtual environment mimicking a space ship. On the screen there is a red light and subjects wait for this red light to become green. They press on a pad each time the red light becomes green

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: virtual reality 2
Description: Subjects are in a virtual environment mimicking a space ship. On the screen there is a red light and subjects wait for this red light to become green. They press on a pad each time the red light becomes green
Study: NCT01819948

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: PhytoMed™
Study: NCT03427268

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PM060184
Description: PM060184: 9.3 mg/m2 PM060184 i.v. as a 30-minute infusion via a central or peripheral venous catheter.Dose can be rounded to the first decimal point.~PM060184 will be administered on Day 1 and Day 8 q3wk. (Three weeks=one treatment cycle).
Study: NCT01493700

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: heated circuit
Description: use electrically heated respiratory circuit (set at 37oC)during mechanical ventilation of anesthetic machine during shoulder arthroscopy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: control
Description: use routine respiratory circuit during mechanical ventilation of anesthetic machine during shoulder arthroscopy
Study: NCT01857700

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Compensation for transport cost

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Compensation for lost wages

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Compensation for transport cost and lost wages

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard of Care
Description: Consistent with standard of care, participants in this group will be offered a refreshment during their office visit.
Study: NCT05299619

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tixel
Description: a thermomechanical system developed for fractional treatment. The system is designed for the treatment of soft tissue by direct conduction of heat, enabling fast water evaporation with low thermal damage to the surrounding tissue (such as charring or ablation).
Study: NCT00287677

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: recombinant human Growth Hormone
Description: Growth Hormone during 6 months (30UG/KG/DAY)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: recombinant human Growth Hormone
Description: Growth Hormone during 6 months (30UG/KG/DAY)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vaccination
Description: Vaccination (Hepatitis A+B + tetanus toxoid) at week 16

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vaccination
Description: Vaccination (Hepatitis A+B + tetanus toxoid) at week 16

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Vaccination
Description: Vaccination (Hepatitis A+B + tetanus toxoid) at week 16

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HAART
Description: HAART all over the trial

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HAART
Description: HAART all over the trial

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HAART
Description: HAART all over the trial
Study: NCT03702491

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: Three to four weeks after surgery, the SOX regimen was given palliative adjuvant chemotherapy for 6-8 cycles, then followed by the second cycle combined with the treatment of apatinib mesylate and the monotherapy maintenance of apatinib mesylate
Study: NCT03919409

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TS-161 Placebo
Description: TS-161 matching placebo capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TS-161 Placebo
Description: TS-161 matching placebo capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TS-161 Placebo
Description: TS-161 matching placebo capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TS-161 Placebo
Description: TS-161 matching placebo capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TS-161 Placebo
Description: TS-161 matching placebo capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TS-161 Placebo
Description: TS-161 matching placebo capsules
Study: NCT01238393

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intravitreal ranibizumab
Description: monthly injections x3 +/- 2nd series of 3
Study: NCT01977183

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: MSPrebiotic
Description: Potato Resistant Starch

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: MSPrebiotic
Description: Potato Resistant Starch

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo - Corn Starch

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo - Corn Starch
Study: NCT01167192

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation therapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Mastectomy (recommended but not mandatory)
Study: NCT03632005

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Vacuum Assisted Closure
Description: Patients will be randomized to receive either standard dressing changes or the Prevena™ System on the day of their operation.

Intervention type: OTHER
Group type: OTHER
Intervention: Sterile dressing
Description: Standard wound care involves the application of an occlusive dressing in the operating room, a dressing change on Post-operative Day 3 and then dressing changes as needed until suture/staple removal on Post-operative Day 14.
Study: NCT04603833

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR3680+Docetaxel
Description: Participants will receive SHR3680 combined with Docetaxel

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SHR3680
Description: Participants will receive SHR3680

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Participants will receive Docetaxel
Study: NCT00892944

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD2516
Description: Fractionated single oral dose
Study: NCT01163955

Intervention type: OTHER
Group type: OTHER
Intervention: Time to fatigue
Description: 5 minutes while playing video games

Intervention type: OTHER
Group type: OTHER
Intervention: Time to fatigue
Description: 5 minutes while playing video games
Study: NCT03716388

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fecal Microbiota Transplantation
Description: Freshly passed stools (80 g) will be diluted with normal saline (200 ml) and homogenized using a blender, filtered, filled into 4 syringes (50 ml each) and used within 1 hour of preparation or 6 hours of passage of stools. Polyethylene glycol lavage will be done for bowel preparation and the slurry administered into the ileum and/or caecum by colonoscopy. Post FMT, recipients will be encouraged to retain the slurry for 4-6 hours. FMT sessions will be scheduled at weeks 0,2,6,10,14.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fecal Microbiota Transplantation
Description: Freshly passed stools (80 g) will be diluted with normal saline (200 ml) and homogenized using a blender, filtered, filled into 4 syringes (50 ml each) and used within 1 hour of preparation or 6 hours of passage of stools. Polyethylene glycol lavage will be done for bowel preparation and the slurry administered into the ileum and/or caecum by colonoscopy. Post FMT, recipients will be encouraged to retain the slurry for 4-6 hours. FMT sessions will be scheduled at weeks 0,2,6,10,14.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mesalamine Granules
Description: Mesalamine granules 4 grams a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mesalamine Granules
Description: Mesalamine granules 4 grams a day

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo infusion
Description: Water with food grade colour to resemble fecal slurry

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo granules
Description: Granules resembling mesalamine granules, 4 grams a day
Study: NCT00217022

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, 3 tablets daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Budesonide
Description: 9 mg daily (three tablets)
Study: NCT06064370

Intervention type: PROCEDURE
Intervention: laparoscopic adrenalectomy
Description: laparoscopic adrenalectomy for pheochromocytoma

Intervention type: PROCEDURE
Intervention: laparoscopic adrenalectomy
Description: laparoscopic adrenalectomy for pheochromocytoma
Study: NCT03788954

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Kinesiotaping
Description: Kinesio tape (KT) is the original elastic adhesive tape for injury prevention, rehabilitation, and performance enhancement. Kinesio Tape is latex-free, hypoallergenic and wearable for days at a time. It has been shown to be clinically effective in joint range of motion promotion,increasing muscle activity and functional performance.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Kinesiotaping
Description: Kinesio tape (KT) is the original elastic adhesive tape for injury prevention, rehabilitation, and performance enhancement. Kinesio Tape is latex-free, hypoallergenic and wearable for days at a time. It has been shown to be clinically effective in joint range of motion promotion,increasing muscle activity and functional performance.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Kinesiotaping
Description: Kinesio tape (KT) is the original elastic adhesive tape for injury prevention, rehabilitation, and performance enhancement. Kinesio Tape is latex-free, hypoallergenic and wearable for days at a time. It has been shown to be clinically effective in joint range of motion promotion,increasing muscle activity and functional performance.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Kinesiotaping
Description: Kinesio tape (KT) is the original elastic adhesive tape for injury prevention, rehabilitation, and performance enhancement. Kinesio Tape is latex-free, hypoallergenic and wearable for days at a time. It has been shown to be clinically effective in joint range of motion promotion,increasing muscle activity and functional performance.
Study: NCT03124550

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exergame Experience
Description: Fitbit Charge HR will be used to measure physical activity and sedentary behavior during waking hours. Each participant will wear a Fitbit for a period of one week at baseline and during the entire 6-week pilot study. Data on step counts, heart rate, and moderate/vigorous activity from the Fitbits will be transmitted wirelessly to our secure research server and will be used to assess changes in physical activity and sedentary behavior over the course of the study. Participants will be instructed to wear the monitor continuously on the wrist. Data will be analyzed using previously validated accelerometer count cut-points for adults after accounting for invalid data and wear time.
Study: NCT01104064

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: real rTMS combined with constraint induced therapy
Description: 10 minutes of priming followed by 10 minutes of low-frequency is followed on the next day with constraint induced therapy. A total of 5 treatment days for each therapy is given.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham rTMS combined with constraint induced therapy
Description: 10 minutes of sham priming followed by 10 minutes of sham low-frequency is followed on the next day with constraint induced therapy. A total of 5 treatment days for each therapy is given.
Study: NCT01262118

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-690,550 (tasocitinib)
Description: CP-690,550 (tasocitinib) dosed at 10 mg BID for 6 weeks in patients with active rheumatoid arthritis
Study: NCT02403284

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liraglutide
Description: Subcutaneous injection by patient

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sugar Pill
Description: Subcutaneous injection daily
Study: NCT02032108

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: lifestyle counselling
Description: A 45-min lifestyle educational session will be delivered to the subjects randomized to the intervention group every month for one year.~Lifestyle intervention will consist in group counselling on dietary habits, effects of regular physical activity, importance of adherence to medications, diabetes complications, actions to control blood sugar and ways of coping with stress.
Study: NCT03702491

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tegafur
Description: 3-4 weeks after operation, 6-8 cycles of adjuvant chemotherapy with simple SOX protocol were given.
Study: NCT03514706

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: volume controlled ventilation
Description: Lung ultrasound (LUS) will be performed with a 2-4 MHz phased array probe. Patients will be scanned in supine position by a recording 5 seconds videos. LUS will be assessed for the presence of B lines.~The sum of lung comets produces a score reflecting the extent of lung water accumulation. LUS will be obtained by scanning 12-rib interspaces. The sum of B-lines on each scanning site yields a score from 0 to 36

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: pressure controlled ventilation
Description: Lung ultrasound (LUS) will be performed with a 2-4 MHz phased array probe. Patients will be scanned in supine position by a recording 5 seconds videos. LUS will be assessed for the presence of B lines.~The sum of lung comets produces a score reflecting the extent of lung water accumulation. LUS will be obtained by scanning 12-rib interspaces. The sum of B-lines on each scanning site yields a score from 0 to 36
Study: NCT02108652

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab 1200 mg given by IV infusion on Day 1 of 21-day cycles until disease progression per RECIST v1.1 criteria/loss of clinical benefit or unmanageable toxicity.
Study: NCT04151823

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: 2 ml per day SMART D3 MATRIX Smartfarma S.r.l. Via San Vittore 40 - 20123 MILAN: 2 mL of product will give 1600 UI/die of VIT D3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Immunofos
Description: Postbiotics will be given at the dose of 80 mg/day. immunofos from Lactobacillus paracasei CNCM I-5220).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Promotion of physical activity
Description: Promotion of physical activity will be encouraged at t0, t1, t2

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Healthy food habits promotion
Description: Promotion of healthy food habits will be encouraged at t0, t1, t2
Study: NCT01182181

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anastrozole (Teva Pharmaceuticals USA)
Description: 1 mg Tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anastrozole (Arimidex®)
Description: 1 mg Tablets
Study: NCT00812838

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 100 units of Botulinum Toxin Type A
Description: Approximately 20 to 30 injections of 100 units of BOTOX® given with a 20 gage needle directly into the penile plaque

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Preservative free normal saline
Description: Approximately 20 to 30 injections of 10cc of preservative free normal saline given with a 20 gage needle directly into the penile plaque

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 100 units Botulinum Toxin A
Description: Approximately 20 to 30 injections of 100 units of BOTOX® given with a 20 gage needle directly into the penile plaque
Study: NCT03758456

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: HAL-MRE1
Description: HAL-MRE1 is a liquid suspension for subcutaneous administration containing aluminum hydroxide adsorbed modified allergens extracted from ragweed pollen.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HAL-MRE1
Description: HAL-MRE1 is a liquid suspension for subcutaneous administration containing aluminum hydroxide adsorbed modified allergens extracted from ragweed pollen.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HAL-MRE1
Description: HAL-MRE1 is a liquid suspension for subcutaneous administration containing aluminum hydroxide adsorbed modified allergens extracted from ragweed pollen.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HAL-MRE1
Description: HAL-MRE1 is a liquid suspension for subcutaneous administration containing aluminum hydroxide adsorbed modified allergens extracted from ragweed pollen.
Study: NCT02610621

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lumpectomy without sentinel node biopsy
Description: Biopsy of the sentinel node is considered standard of care treatment for women with localized breast cancer. The procedure will be eliminated at time of lumpectomy.
Study: NCT03762083

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: pHyph, Gedea pessary
Description: pHyph is a vaginal tablet for the treatment of BV.
Study: NCT01534806

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac
Description: Ketorolac(0.5mg/kg) IV push

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sodium Chloride 0.9% - 10 mL IV push
Study: NCT02597036

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3127804
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3127804
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3127804
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3127804
Description: Administered IV
Study: NCT03693469

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality
Description: Participants wear a Virtual Reality headset that consists of a ASUS phone and a VOX+ Z3 3D Virtual Reality Headset. The phone runs the VR Roller Coaster app to produce the virtual environment.
Study: NCT02597036

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3127804
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramucirumab
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramucirumab
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramucirumab
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramucirumab
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Administered IV
Study: NCT04237714

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smiling is fun
Description: Smile is Fun is a self-applied program that combines elements of prevention and psychological treatment for emotional disorders. It is delivered via the Internet and it is based on CBT technics. The program consists of 8 therapeutic modules and includes 3 transversal tools (activity report, calendar, how am I?) to provide feedback and accompany patients during the intervention. The program requires 8 to 10 weeks to complete in its entirety.~The intervention, initially developed in Spain, will be adapted to the Ecuadorian culture including elements of the local population, such as, dialect, personal stories, examples and activities. The Ecuadorian version will be evaluate by health professional and users of public health system of Ecuador.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smiling is fun
Description: Smile is Fun is a self-applied program that combines elements of prevention and psychological treatment for emotional disorders. It is delivered via the Internet and it is based on CBT technics. The program consists of 8 therapeutic modules and includes 3 transversal tools (activity report, calendar, how am I?) to provide feedback and accompany patients during the intervention. The program requires 8 to 10 weeks to complete in its entirety.~The intervention, initially developed in Spain, will be adapted to the Ecuadorian culture including elements of the local population, such as, dialect, personal stories, examples and activities. The Ecuadorian version will be evaluate by health professional and users of public health system of Ecuador.
Study: NCT02767102

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Red wine with melatonin
Description: Twelve healthy volunteers will be recruited to receive both 125 mL of red wine rich in MLT (10 ng mL-1)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Red wine without melatonin
Description: Twelve healthy volunteers will be recruited to receive both 125 mL of red wine without MLT
Study: NCT03440983

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI data acquiring in healthy volunteers
Description: The quality of the images, cartographies or spectres will be compared to standard acquisitions. This evaluation will be based on qualitative visual criteria assessed by expert radiologists or on quantitative criteria assessed by data processing tools
Study: NCT02654613

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality Improvement Model of Care
Description: QI addresses the how of program implementation. Technically, QI improves process performance by developing a common simplified view of the components and linkages of integrated care, real-time data feed-back to track system performance, understanding the psychology of system change, and crucially, the iterative testing and incorporation of ideas for performance improvement from the front-line practitioners, managers, and customers in the local context.
Study: NCT00799136

Intervention type: DRUG
Group type: OTHER
Intervention: R-EPOCH and cART
Description: This is a prospective, single-arm, multi-centre, phase II trial of immuno-chemotherapy (rituximab and EPOCH) with mandatory combination antiretroviral therapy for initial treatment of AIDS-related lymphoma.
Study: NCT04057664

Intervention type: BEHAVIORAL
Intervention: Learning of Coping Strategies
Description: Group sessions with psychotherapy and physiotherapy
Study: NCT01576913

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Music listening
Description: Listening to tempo music while cycling in an exercise test